This study focuses on patients with neovascular age-related macular degeneration, a condition where abnormal blood vessels grow in the back of the eye, affecting central vision. The research evaluates a medication called faricimab (also known as RO6867461), which is given as an injection into the eye (intravitreal injection). This medicine works by targeting specific proteins that cause abnormal blood vessel growth in the eye.

The purpose of this study is to determine how well faricimab works and how safe it is when given to patients over extended periods, with treatments spaced up to 24 weeks apart. The medication is provided as a solution for injection with a strength of 120 mg/mL. During the study, participants will receive eye injections according to different schedules, and their vision will be monitored regularly.

The study will track changes in participants’ vision and examine the thickness of specific layers in the retina over time. The treatment period lasts for approximately 96 weeks, during which patients will receive regular eye examinations and vision tests. The study will monitor both the benefits of the treatment and any side effects that may occur in the eye or elsewhere in the body.